PredictIve value of EMVI detected by MDCT combined with CA19-9 for prognosis of stage III colon caner patients

周静,姚旬,张辉,崔艳成,申占龙,叶颖江,王屹,王杉
DOI: https://doi.org/10.19538/j.cjps.issn1005-2208.2017.01.25
2017-01-01
Abstract:Objecetive To investigate the ability of extramural vascular invasion(EMVI) in predicting 3-years disease-free survival(3yr DFS)of patients with colon cancer. Methods Between February 2009 and December 2013, patients who had histologically proven primary colon cancer and underwent curative resection were included in this retrospective study. EMVI was defined as tumor tissue in adjacent vessels beyond colon wall on MDCT. DFS was defined as the time from the date of curative resection to the date of local recurrence,and/or distant disease,or tumor-related death. Univariate and multivariate analysis were conducted to identify prognostic factors associated with 3yr DFS. Kaplan-Meier analyses were used to compare 3yr DFS. Cox’s proportional hazards models were used to measure the impact of confounding variables on survival rates. Chi-square test was used to analyze the difference of recurrent/metastatic rate. Results In final,90 patients were included in this study that were identified as stageⅢpatients by pathology based on American Joint Committee on Cancer (AJCC). Multivariate analysis showed that elevated serum CA19-9(HR=2.229,95%CI 1.040-4.776,P=0.039)and EMVI positive(HR=3.266,95%CI 1.648-7.173,P=0.003) were identified as independent predictors of 3yr DFS in stageⅢcolon cancer. Cumulative 3-year DFS were 52.8%and 81.5%(95%CI 1.648-7.173)for EMVI positive and negative patients,and 55.6%and 76.6%(95%CI 1.040-4.776)for elevated serum CA19-9 and normal serum CA19-9,significances were seen (P<0.05). Compared with ctEMVI positive combined with elevated serum CA19-9,3yr recurrent/metastatic rate of ctEMVI negative combined with normal serum CA19-9 was lowerer significantly (10.5%vs. 54.5%,P<0.05).Conclusion EMVI detected with ceMDCT, and elevated serum CA19-9 level could be used as independent predictors of 3yr DFS in patients with stageⅢ colon cancer.
What problem does this paper attempt to address?